A Phase 4 interventional study of GONAL f® prefilled pen and GONAL f® prefilled pen in Infertility, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Switzerland. Open to female participants aged 18 Years to 34 Years. Per ClinicalTrials.gov, last updated 2014-02-13.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.
Among the 30 studies testing follitropin alfa in Infertility, this one is the 12th largest by enrollment, is the only one that started in 2008, is one of 13 in phase 4, and was the 6th registered.
2,088 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:
Vietnam Military Medical University · Sites in Vietnam
Ages 18–34 · Women only
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Sites in Japan
Ages 18–42 · Women only
Nanjing University · Sites in China
Ages 35–40 · Women only
By country, each count listing its studies:
follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 34 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 159 across the 30 interventional studies. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 30 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
44 studies in Infertility by Merck KGaA, Darmstadt, Germany: 1 open now, 1 under way, 1 of them phase 3. Of 43 finished, 21 (49%) have results posted.
Among the 44 studies in Infertility by Merck KGaA, Darmstadt, Germany, this one is the 10th largest by enrollment of the 31 interventional ones that give a count, is one of 7 that started in 2008, is one of 9 in phase 4, and was the 8th registered.
Merck KGaA, Darmstadt, Germany’s Infertility studies by the year they started, since 1999.
2 of the studies testing follitropin alfa in Infertility that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340827Phase 3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyA Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) | 2027-09-30 |
| NCT06571214Nanjing UniversityPotential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment | 2026-12-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies testing follitropin alfa in Infertility, from their registry updates:
Among Merck KGaA, Darmstadt, Germany’s 44 in Infertility:
This tab as a report to print or save as PDF → With an account.
The overall objective of this trial is to compare the ovarian response in assisted reproductive technology (ART) subjects administered GONAL f® according to the 'Consistency in recombinant follicle stimulating hormone [r-FSH] starting doses for individualized treatment' (CONSORT) calculator versus given a standard GONAL f® dose of 150 International Unit (IU) per day.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GONAL-f® dose based on subject baseline characteristics determined according to the CONSORT calculator
Drug: GONAL f® prefilled pen
GONAL-f® at a standard dose of 150 IU per day
Drug: GONAL f® prefilled pen
GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only
Also known as: Follitropin alfa, Recombinant human follicle stimulating hormone (r-hFSH), GONAL-f® Prefilled Pen
GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.
Also known as: Follitropin alfa, r-hFSH, GONAL-f® Prefilled Pen
Number of Oocytes Retrieved Per Participant
Mean number of oocytes retrieved on the day of ovum pick up (OPU) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.
Time frame: 34-38 hours post-recombinant human choriogonadotropin (hCG) (OPU)
Total GONAL-f® Dose
Time frame: Start of treatment until end of stimulation cycle (approximately 28 days)
Mean GONAL-f® Daily Dose
Time frame: Start of treatment until end of stimulation cycle (approximately 28 days)
Total Number of GONAL-f® Stimulation Treatment Days
Time frame: Start of treatment until end of stimulation cycle (approximately 28 days)
Number of Participants With Cancelled Cycles Due to Excessive or Inadequate Response to Treatment
Number of participants with cancelled cycles due to excessive or inadequate response was evaluated. An excessive response: greater than or equal to 25 oocytes which could put the participant at risk of OHSS; An inadequate response: defined as 3 or less follicles of greater than or equal to 12 millimeter (mm) developing following at least 7 days of GONAL-f® treatment.
Time frame: Start of treatment until Day 15-20 post-hCG
Percentage of Participants With Biochemical Pregnancies
Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum and that does not develop into a clinical pregnancy.
Time frame: Start of treatment until Day 15-20 Post-hCG
Number of Participants With Fetal Sacs and Fetal Hearts
Number of participants with fetal sacs and fetal hearts (with activity) as seen on an ultrasound scan to confirm clinical pregnancy.
Time frame: Day 35-42 Post-hCG
Implantation Rate
Implantation rate was measured as the number of gestational sacs observed divided by the number of embryos transferred multiplied by 100.
Time frame: Day 35-42 Post-hCG
Number of Participants With Multiple Pregnancies
Multiple pregnancy was defined as 2 or more fetal hearts with activity.
Time frame: Day 35-42 Post-hCG
Serum Progesterone (P4) Levels
Time frame: End of stimulation cycle (approximately 28 days)
Percentage of Participants With Clinical Pregnancy
Clinical pregnancy is defined by the number of sacs and hearts with activity per ultrasound scan performed on Day 35-42 post-hCG.
Time frame: Day 35-42 Post-hCG
Number of Participants With OHSS
OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.
Time frame: Start of treatment until Day 15-20 Post-hCG
Pregnancy Outcome - Number of Participants With Pregnancy and Their Outcome
Pregnancy outcomes are live outcome (live infant) and non-live outcome (non-live infant) or unknown outcome (subject lost to follow-up).
Time frame: up to 9 month (following the end of treatment)
Participants were enrolled at 22 clinical trial centers in 9 European countries and 1 center in Chile. Recruitment period: 29 August 2008 to 21 January 2010.
| Milestone | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Started | 96 | 104 |
| Completed | 82 | 83 |
| Not completed | 14 | 21 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lack of ovarian response to stimulation | 9 | 5 |
| Withdrew: Ovarian hyperstimulation syndrome (ohss) | 1 | 6 |
| Withdrew: No fertilization | 2 | 2 |
| Withdrew: All embryos discarded | 0 | 3 |
| Withdrew: No embryo cleavage | 0 | 2 |
Mean number of oocytes retrieved on the day of ovum pick up (OPU) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.
| oocytes | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Number of Oocytes Retrieved Per Participant | 10.0 ± 5.6 | 11.8 ± 5.3 |
| IU | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Total GONAL-f® Dose | 1288.54 ± 300.95 | 1809.95 ± 546.90 |
| IU | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Mean GONAL-f® Daily Dose | 121.49 ± 22.56 | 167.43 ± 30.79 |
| days | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Total Number of GONAL-f® Stimulation Treatment Days | 10.6 ± 1.7 | 10.7 ± 1.6 |
Number of participants with cancelled cycles due to excessive or inadequate response was evaluated. An excessive response: greater than or equal to 25 oocytes which could put the participant at risk of OHSS; An inadequate response: defined as 3 or less follicles of greater than or equal to 12 millimeter (mm) developing following at least 7 days of GONAL-f® treatment.
| Participants | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Inadequate response | 9 | 5 |
| Excessive response (Risk of OHSS) | 1 | 6 |
Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum and that does not develop into a clinical pregnancy.
| percentage of participants | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Percentage of Participants With Biochemical Pregnancies | 47.7 | 44.1 |
Number of participants with fetal sacs and fetal hearts (with activity) as seen on an ultrasound scan to confirm clinical pregnancy.
| participants | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Missing (fetal sacs and fetal hearts) | 47 | 57 |
| 0 (fetal sacs) | 6 | 1 |
| 1 (fetal sacs) | 27 | 25 |
| 2 (fetal sacs) | 5 | 10 |
| 3 (fetal sacs) | 1 | 0 |
| 0 (fetal hearts) | 8 | 3 |
| 1 (fetal hearts) | 25 | 24 |
| 2 (fetal hearts) | 5 | 9 |
| 3 (fetal hearts) | 1 | 0 |
Implantation rate was measured as the number of gestational sacs observed divided by the number of embryos transferred multiplied by 100.
| percent sacs per embryo | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Implantation Rate | 31.1 ± 41.3 | 31.2 ± 40.8 |
Multiple pregnancy was defined as 2 or more fetal hearts with activity.
| participants | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Number of Participants With Multiple Pregnancies | 6 | 9 |
| nmol/L | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Serum Progesterone (P4) Levels | 5.41 ± 7.57 | 4.88 ± 2.22 |
Clinical pregnancy is defined by the number of sacs and hearts with activity per ultrasound scan performed on Day 35-42 post-hCG.
| percentage of participants | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Percentage of Participants With Clinical Pregnancy | 36.0 | 35.5 |
OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.
| participants | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Number of Participants With OHSS | 6 | 13 |
Pregnancy outcomes are live outcome (live infant) and non-live outcome (non-live infant) or unknown outcome (subject lost to follow-up).
| participants | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Live outcomes | 24 | 25 |
| Non-live outcomes | 2 | 3 |
| Unknown outcomes | 5 | 5 |
Collected over Adverse Events (AEs) were collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until the final treatment examination, on Day 15-20 of the post-treatment assessment period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GONAL-f ® CONSORT Calculator | — | 4/96 (4.2%) | 40/96 (41.7%) |
| GONAL-f ® Standard Treatment | — | 3/104 (2.9%) | 48/104 (46.2%) |
| Event | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 2/96 | 2/104 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/96 | 0/104 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 1/96 | 0/104 |
| UrticariaSkin and subcutaneous tissue disorders | 0/96 | 1/104 |
| Event | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment |
|---|---|---|
| HeadacheNervous system disorders | 18/96 | 25/104 |
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 5/96 | 11/104 |
| Adnexa uteri painReproductive system and breast disorders | 9/96 | 8/104 |
| Procedural painInjury, poisoning and procedural complications | 9/96 | 5/104 |
| NauseaGastrointestinal disorders | 8/96 | 9/104 |
| Abdominal distensionGastrointestinal disorders | 8/96 | 3/104 |
| Age, Categorical(Participants) | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 96 | 104 | 200 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment | Total |
|---|---|---|---|
| Mean | 30.0 ± 2.9 | 30.6 ± 2.6 | 30.3 ± 2.8 |
| Sex: Female, Male(Participants) | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment | Total |
|---|---|---|---|
| Female | 96 | 104 | 200 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment | Total |
|---|---|---|---|
| Chile | 7 | 8 | 15 |
| Denmark | 26 | 26 | 52 |
| France | 6 | 5 | 11 |
| Germany | 13 | 16 | 29 |
| Italy | 10 | 10 | 20 |
| Netherlands | 5 | 6 | 11 |
| Spain | 4 | 6 | 10 |
| Sweden | 8 | 7 | 15 |
| Switzerland | 11 | 14 | 25 |
| United Kingdom | 6 | 6 | 12 |
| Serum Anti-Mullerian Hormone (AMH)(nanogram/milliliter (ng/mL)) | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment | Total |
|---|---|---|---|
| Mean | 2.705 ± 1.870 | 2.399 ± 1.492 | 2.551 ± 1.692 |
| Serum Progesterone (P4)(nanomole/liter (nmol/L)) | GONAL-f ® CONSORT Calculator | GONAL-f ® Standard Treatment | Total |
|---|---|---|---|
| Mean | 2.934 ± 2.328 | 2.803 ± 2.291 | 2.868 ± 2.303 |
The record gives a start of Aug 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin alfa
Merck KGaA, Darmstadt, Germany →